Ascendis Pharma Files 6-K for December 2024
Ticker: ASND · Form: 6-K · Filed: Dec 17, 2024 · CIK: 1612042
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, registration
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K on Dec 17, 2024, for its monthly reporting.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on December 17, 2024, to report information as a foreign private issuer. The filing is for the month of December 2024 and is incorporated by reference into several Form S-8 registration statements. The company is incorporated in G7 and its fiscal year ends on December 31.
Why It Matters
This filing serves as an update for Ascendis Pharma A/S as a foreign private issuer, potentially containing material information relevant to investors.
Risk Assessment
Risk Level: low — This is a routine monthly filing by a foreign private issuer and does not appear to contain significant new financial or operational disclosures.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 0001193125-24-280059 (accession_number) — Filing identifier
- 20241217 (date) — Filing date
- Tuborg Boulevard 12 DK-2900 Hellerup Denmark (address) — Principal executive offices
- 333-203040 (registration_number) — Form S-8 registration
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of Ascendis Pharma A/S, a foreign private issuer, pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of December 2024.
When was this Form 6-K filed?
This Form 6-K was filed on December 17, 2024.
What is Ascendis Pharma A/S's principal executive office address?
Ascendis Pharma A/S's principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Under which SEC Act is this filing made?
This filing is made under the Securities Exchange Act of 1934.
Into which registration statements is this report incorporated by reference?
This report on Form 6-K is deemed to be incorporated by reference into the registration statements on Form S-8 with Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, and 333-216883.
Filing Stats: 812 words · 3 min read · ~3 pages · Grade level 20 · Accepted 2024-12-17 06:04:27
Key Financial Figures
- $100 million — ment, Ascendis is eligible to receive a $100 million milestone payment from Novo Nordisk. Ad
Filing Documents
- d918920d6k.htm (6-K) — 14KB
- 0001193125-24-280059.txt ( ) — 15KB
Forward-Looking Statements
Forward-Looking Statements This report contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding Ascendis future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the expected initial targets of the GLP-1 receptor agonist product candidate and (ii) Ascendis receipt of the $100 million milestone payment. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on collaboration partners to develop and conduct clinical studies with, obtain regulatory approvals for, market and sell product candidates; dependence on third party manufacturers, distributors and service providers for Ascendis products and product candidates; unforeseen safety or efficacy results in Ascendis development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis ability to obtain additional funding, if needed, to support its business activities; and the impact of
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: December 17, 2024 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer